PI3K/Akt/mTOR Signaling


The PI3K/Akt/mTOR signaling pathway is a key regulator in growth, survival, cell cycle proliferation, protein synthesis and glucose metabolism. Growth factors, hormones, and cytokines can activate this pathway by binding their cognate receptor tyrosine kinase (RTK), cytokine receptor, or GPCR, resulting in the activation of lipid kinase PI3K which produces PIP3 at the plasma membrane.
The binding of PIP3 translocates Akt to cell membranes, enables Akt activation through phosphorylation at Thr308 mediated by phosphoinositide dependent kinase 1 (PDK1). In addition, Akt is phosphorylated at Ser473 by the mTOR-rictor complex, mTORC2. PTEN is a negative regulator of Akt signaling that reverses the function of PI3K by removing 3’-phosphate groups. Akt activity is also negatively regulated by the phosphatases PP2A and PHLPP. Akt propagates its signal to affect DNA transcription, cell cycle and apoptosis. Akt can activate mTOR directly by phosphorylation or indirectly, by phosphorylation and inactivation of mTOR inhibitor TSC2 and PRAS40. Together these mechanisms stimulate cell growth and G1 cell cycle progression through signaling via p70 S6 Kinase and inhibition of 4E-BP1. Defects in PI3K/AKT/mTOR signaling are implicated in cancer, diabetes and cardiovascular disease etc.
-
A4785 Musk ketone -
A8963 FR054 -
A8966 AKT Kinase Inhibitor -
A9055 YY-20394 -
BA2723 AZD-7648Summary: AZD-7648 is a selective and orally effective inhibitor. -
BA2732 IsoginkgetinSummary: Isoginkgetin is an inhibitor. -
BA2740 3BDOSummary: 3BDO is a new type of activator. -
BA2746 Deferoxamine5 CitationSummary: Deferoxamine (DeferoxamineB) is an iron chelator (binding Fe(III) and many other metal cations) that is widely used to reduce iron accumulation and deposition in tissues. -
BA2757 STL127705Summary: STL127705 is a potent inhibitor of Ku70/80 heterodimeric proteins. -
BA2793 9-ING-41Summary: 9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective inhibitor of glycogen synthase kinase-3β.

